Dongin (Donoven) Kim, Ph.D.

Assistant Professor
Pharmaceutical Sciences
Phone (405) 271-6593 x 47473
Office College of Pharmacy, CPB 317
Email dongin-kim@ouhsc.edu
Publications & Presentations
- 1. Kim D. SORL1-Mediated EGFR and FGFR4 Regulation Enhances Chemoresistance in Ovarian Cancer . Cancers. 2025; 17
2. Kim D. Exosomes in diagnostic and therapeutic applications of ovarian cancer. J. Ovarian Res.. 2024; 17
3. Kim D. Mature microRNA-binding protein QKI suppresses extracellular microRNA let-7b release. J Cell Sci. 2024; 137
4. Kim D. Minimal information for studies of extracellular vesicles (MISEV 2023): From basic to advanced approaches . Journal of Extracellular Vesicles . 2024; 13 : e12404
5. Kim D. Nanoparticles loaded with IL-2 and TGF-b promote transplantation tolerance to alloantigen. Front. Immunol.. 2024; 15
Grants
- 6. Preclinical assessment of exosomal drug delivery system using innovative tumor mouse model. Misc Non-Federal. Start Date: 2024. End Date: 2024.
7. Role of Renal Lymphatics in Blood Pressure Regulation. NIH. Start Date: 2018. End Date: 2023.
8. Cancer exosome mediated antibody production for active tumor targeting treatment. Non-federal. Start Date: 2022. End Date: 2023.
9. Engineering Exosome for Ovarian Cancer Targeting Therapy. NIH. Start Date: 2021. End Date: 2023.
10. Exosome based intraocular therapy combined with active targeting of ocular neovascularization. NIH. Start Date: 2022. End Date: 2022.
Awards and Honors
no results
Education
- 1. Degree: Ph D. University of Utah. Date: 2009.
2. Degree: MS. University of Florida. Date: 2002.
3. Degree: BS. Ajou University. Date: 1999.
Administrative Assignments
no results